Placeholder

Lymecycline

CAS No:
992-21-2 Categories: , ,
  • # LGM Pharma is a Lymecycline CAS# 992-21-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Lymecycline
  • CAS #: 992-21-2
  • Mode of Action:

    Lymecycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Lymecycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Cells become resistant to lymecycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps lymecycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents lymecycline from acting on the ribosome.

  • Pharmacodynamics:

    Lymecycline is a tetracycline broad-spectrum antibiotic. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed. It inhibits cell growth by inhibiting translation.

  • Toxicity:

    Adverse effects include nausea, vomiting, diarrhoea, glossitis, enterocolitis, dysphagia, dermatitis, hypersensitivity reactions, proctitis, and vaginitis.

  • IUPAC: (2S)-6-[({[(4S, 4aS, 5aS, 6S, 12aS)-4-(dimethylamino)-3, 6, 10, 12, 12a-pentahydroxy-6-methyl-1, 11-dioxo-1, 4, 4a, 5, 5a, 6, 11, 12a-octahydrotetracen-2-yl]formamido}methyl)amino]-2-aminohexanoic acid
  • ATC: J01AA04
  • PubChem: 24757945
  • DrugBank: DB00256 (APRD00565, EXPT01049)
  • Formula: C16H13ClN2O
  • Molecular Mass: 602.6328
  • Synonyms: 7-Chlorotetracycline Chlorotetracycline Chlorotetracycline hydrochloride Chlortetracyclin Chlortetracycline Chlortetracycline hydrochloride Chlortetracyclinium chloride CLTC
  • SMILES: CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
  • InChl: AHEVKYYGXVEWNO-UEPZRUIBSA-N
  • General Reference:

    1. Link
    2. Meynadier J, Alirezai M: Systemic antibiotics for acne. Dermatology. 1998;196(1):135-9. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service